Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Conditions

• Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Interventions

• BIOLOGICAL: Samalizumab (BAML-16-001-S1)
• BIOLOGICAL: BI 836858 (BAML-16-001-S2)
• OTHER: Laboratory Biomarker Analysis
• DRUG: Daunorubicin (BAML-16-001-S1)
• DRUG: Cytarabine (BAML-16-001-S1)
• DRUG: Azacitidine (BAML-16-001-S2)
• DRUG: AG-221 (BAML-16-001-S3)
• DRUG: Azacitidine (BAML-16-001-S3)
• DRUG: Entospletinib (BAML-16-001-S4)
• DRUG: Azacitidine (BAML-16-001-S4)
• DRUG: Entospletinib (BAML-16-001-S5)
• DRUG: Decitabine (BAML-16-001-S5)
• DRUG: Entospletinib (BAML-16-001-S6)
• DRUG: Daunorubicin (BAML-16-001-S6)
• DRUG: Cytarabine (BAML-16-001-S6)
• DRUG: Pevonedistat (BAML-16-001-S9)
• DRUG: Azacitidine (BAML-16-001-S9)
• DRUG: AG-120 (BAML-16-001-S16)
• DRUG: Azacitidine (BAML-16-001-S16)
• DRUG: Gilteritinib (BAML-16-001-S8 Group 1)

Sponsor

Beat AML, LLC